Summary & Overview
HCPCS J2680: Fluphenazine Decanoate Injection, up to 25 mg
HCPCS Level II code J2680 denotes the injectable antipsychotic fluphenazine decanoate, billed per unit of up to 25 mg. This code is used when recording administration of a long-acting depot formulation commonly employed in the management of schizophrenia and other chronic psychotic disorders. Nationally, accurate use of J2680 matters for clinical tracking of long-acting antipsychotic therapy, claims processing, and population-level monitoring of medication utilization in behavioral health.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for depot fluphenazine injections, the typical sites of service where these injections occur, and the administrative definitions tied to the HCPCS Level II code. The publication also provides benchmarking context where available, notes on billing practices and common modifier usage, and any recent policy or coding updates that affect coverage and claims adjudication. Where input data is incomplete, specific fields are noted as not available. The material is intended for a national audience of billing professionals, compliance officers, and clinical administrators seeking a clear, operational summary of HCPCS Level II code J2680 and its application in outpatient behavioral health settings.
Billing Code Overview
HCPCS Level II code J2680 represents the administration of fluphenazine decanoate as an injectable antipsychotic formulation, with unit definition up to 25 mg per dosage. The service type is an injectable long-acting antipsychotic medication administration. The typical site of service is outpatient clinics, behavioral health clinics, psychiatric centers, and community mental health settings, where depot antipsychotic injections are administered on a recurring schedule.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 45-year-old patient with chronic schizophrenia stabilized on depot antipsychotic therapy presents to an outpatient behavioral health clinic for a scheduled intramuscular injection of long‑acting fluphenazine decanoate. The patient has been receiving maintenance injections every 2–4 weeks to improve adherence and prevent relapse. The visit workflow includes verification of identity and medication orders, assessment of vital signs and mental status, review of recent side effects (extrapyramidal symptoms, sedation, orthostatic hypotension), confirmation of informed consent for depot therapy, and documentation of the lot number and dose administered. The nurse prepares the J2680 product (fluphenazine decanoate, up to 25 mg), performs an intramuscular gluteal or deltoid injection using aseptic technique, monitors the patient for 15–30 minutes for acute adverse reactions, and updates the electronic medical record with administration details, next appointment, and any required prior authorization or payer notes. Typical sites of service are outpatient behavioral health clinics, community mental health centers, psychiatric outpatient departments, or primary care offices managing stable patients on long‑acting injectable antipsychotics. Typical patient scenario modifiers could include routine scheduled maintenance administration or medically necessary adjustments for dose changes or adverse reaction management.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 |